Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers

Veronika Rockova, Saman Abbas, Bas J. Wouters, Claudia A. J. Erpelinck, H. Berna Beverloo, Ruud Delwel, Wim L. J. van Putten, Bob Löwenberg, Peter J. M. Valk

Blood (2011) 118 (4): 1069–1076.

https://doi.org/10.1182/blood-2011-02-334748

Published: 2011

Includes: Supplemental data

Journal Articles

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

Erdogan Taskesen, Lars Bullinger, Andrea Corbacioglu, Mathijs A. Sanders, Claudia A. J. Erpelinck, Bas J. Wouters, Sonja C. van der Poel-van de Luytgaarde, Frederik Damm, Jürgen Krauter, Arnold Ganser, Richard F. Schlenk, Bob Löwenberg, Ruud Delwel, Hartmut Döhner, Peter J. M. Valk, Konstanze Döhner

Blood (2011) 117 (8): 2469–2475.

https://doi.org/10.1182/blood-2010-09-307280

Published: 2011

Includes: Supplemental data

Journal Articles

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

Bas J. Wouters, Bob Löwenberg, Claudia A. J. Erpelinck-Verschueren, Wim L. J. van Putten, Peter J. M. Valk, Ruud Delwel

Blood (2009) 113 (13): 3088–3091.

https://doi.org/10.1182/blood-2008-09-179895

Published: 2009

Includes: Supplemental data

Journal Articles

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features

Maria E. Figueroa, Bas J. Wouters, Lucy Skrabanek, Jacob Glass, Yushan Li, Claudia A. J. Erpelinck-Verschueren, Anton W. Langerak, Bob Löwenberg, Melissa Fazzari, John M. Greally, Peter J. M. Valk, Ari Melnick, Ruud Delwel

Blood (2009) 113 (12): 2795–2804.

https://doi.org/10.1182/blood-2008-08-172387

Published: 2009

Includes: Supplemental data

Journal Articles

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated

Sanne Lugthart, Ellen van Drunen, Yvette van Norden, Antoinette van Hoven, Claudia A. J. Erpelinck, Peter J. M. Valk, H. Berna Beverloo, Bob Löwenberg, Ruud Delwel

Blood (2008) 111 (8): 4329–4337.

https://doi.org/10.1182/blood-2007-10-119230

Published: 2008

Includes: Supplemental data

Journal Articles

Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARα

Sake van Wageningen, Marleen C. Breems-de Ridder, Jeannet Nigten, Gorica Nikoloski, Claudia A. J. Erpelinck-Verschueren, Bob Löwenberg, Theo de Witte, Daniel G. Tenen, Bert A. van der Reijden, Joop H. Jansen

Blood (2008) 111 (3): 1634–1643.

https://doi.org/10.1182/blood-2007-04-081125

Published: 2008

Includes: Supplemental data

Journal Articles

Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1

Bas J. Wouters, Meritxell Alberich Jordà, Karen Keeshan, Irene Louwers, Claudia A. J. Erpelinck-Verschueren, Dennis Tielemans, Anton W. Langerak, Yiping He, Yumi Yashiro-Ohtani, Pu Zhang, Christopher J. Hetherington, Roel G. W. Verhaak, Peter J. M. Valk, Bob Löwenberg, Daniel G. Tenen, Warren S. Pear, Ruud Delwel

Blood (2007) 110 (10): 3706–3714.

https://doi.org/10.1182/blood-2007-02-073486

Published: 2007

Includes: Supplemental data

Journal Articles

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

Roel G. W. Verhaak, Chantal S. Goudswaard, Wim van Putten, Maarten A. Bijl, Mathijs A. Sanders, Wendy Hugens, André G. Uitterlinden, Claudia A. J. Erpelinck, Ruud Delwel, Bob Löwenberg, Peter J. M. Valk

Blood (2005) 106 (12): 3747–3754.

https://doi.org/10.1182/blood-2005-05-2168

Published: 2005

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated

Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARα

Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only